Last reviewed · How we verify
NCT07520214
Clinical Study on the Safety and Immunogenicity of Specific Cancer Vaccines in Preventing Recurrence of Glioblastoma
EARLY_PHASE1 trial testing mRNA vaccine: GV-907、GV-108 in Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype in 9 participants. Enrolling by invitation.
31 December 2027
Quick facts
| Lead sponsor | Beijing Neurosurgical Institute |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | ENROLLING BY INVITATION |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | sequential |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 9 |
| Start date | 10 September 2025 |
| Primary completion | 31 December 2027 |
| Estimated completion | 31 December 2027 |
| Sites | 1 location across China |
Drugs / interventions tested
- mRNA vaccine: GV-907、GV-108
Conditions studied
- Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype — all drugs for Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype →
- Glioblastom WHO Grade 4 — all drugs for Glioblastom WHO Grade 4 →
Sponsor
Beijing Neurosurgical Institute
Who can join
18 and older, any sex, with Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype or Glioblastom WHO Grade 4. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study evaluates the safety and specific antitumor immune responses of mRNA vaccines GV-108 and GV-907 in IDH-wildtype glioblastoma patients.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07520214
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
Currently open trials in the same condition.
- NCT05879367 — Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma · Phase 1 · recruiting
Other Beijing Neurosurgical Institute trials
Trials by the same sponsor.
- NCT07285525 — Accelerating Motor Recovery in Glioma Patients Using Postoperative nrTMS · NA · active not recruiting
- NCT06585527 — Clinical Study on the Safety and Efficacy of TS-2021 in the Treatment of Recurrent Malignant Glioma · Phase 1 · recruiting
- NCT05803057 — Accelerating Motor Recovering in Patients With SMA Syndrome After Glioma Surgery by Using nrTMS · NA · unknown
- NCT07335029 — Investigation of Hemodynamics and Radiomics Based on High Resolution Magnetic Resonance Imaging for Predicting the Outco · active not recruiting
- NCT04425798 — Connectivity Alterations After Levetiracetam Application · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07520214 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Beijing Neurosurgical Institute
- Last refreshed: 9 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07520214.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing